Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Addex Therapeutics Ltd (ADR) (ADXN)
:ADXN
Earnings Data
Report Date
Mar 06, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-1.42Last Year’s EPS
-4.06Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 22, 2024
|% Change Since: -9.25%
|Next Earnings Date:Mar 06, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in R&D programs, particularly with the GABAB PAM program and Neurosterix advancements, while also pointing out decreased revenue and potential financial risks related to Neurosterix. Despite some financial challenges, the strategic progress and strong cash position provide a positive outlook.Company Guidance
During the third quarter 2024 earnings call for Addex Therapeutics, the company provided detailed guidance on their ongoing and future projects. The GABAB positive allosteric modulator (PAM) program, in collaboration with Indivior, is progressing with the initiation of IND-enabling studies for a compound targeting substance use disorders. Addex could achieve up to USD 330 million in regulatory, clinical, and commercial milestones from this partnership, along with tiered royalties from net sales. Additionally, Addex is advancing its independent GABAB PAM program to treat chronic cough, with plans to begin IND-enabling studies in 2025. Financially, Addex reported CHF 0.1 million in income from continuing operations for Q3 2024, with CHF 3.3 million in cash reserves. The company is actively working on repositioning dipraglurant for brain injury recovery and continues its collaboration with Neurosterix, which has started IND-enabling studies for its M4 PAM program.Progress in GABAB PAM Program
Addex Therapeutics made excellent progress in their GABAB positive allosteric modulator program with the completion of the R&D phase and the selection of a compound for development in substance use disorder by their partner, Indivior. IND-enabling studies have started.
Neurosterix Advancements
The spin-out company, Neurosterix, has made excellent progress, starting IND-enabling studies with its M4 PAM program.
Strong Financial Position
Addex Therapeutics is in a solid position with a strong balance sheet, holding CHF 3.3 million in cash and other assets, providing a solid foundation to deliver on strategic objectives.
---
ADXN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ADXN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 22, 2024 | $8.11 | $7.53 | -7.15% |
| Sep 30, 2024 | $9.05 | $9.77 | +7.96% |
| Jun 06, 2024 | $8.99 | $9.20 | +2.34% |
| Apr 18, 2024 | $22.00 | $20.96 | -4.73% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Addex Therapeutics Ltd (ADR) (ADXN) report earnings?
Addex Therapeutics Ltd (ADR) (ADXN) is schdueled to report earning on Mar 06, 2025, TBA Not Confirmed.
What is Addex Therapeutics Ltd (ADR) (ADXN) earnings time?
Addex Therapeutics Ltd (ADR) (ADXN) earnings time is at Mar 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ADXN EPS forecast?
ADXN EPS forecast for the fiscal quarter 2024 (Q4) is -1.42.
---